This bill directs HHS, through the FDA Commissioner, to create a multi-agency GRAS Review Board to examine ‘‘covered GRAS designations’’ — defined as manufacturer determinations made before 2000 that a substance is generally recognized as safe and that were never filed as food additive petitions or notified to FDA. The Board must identify covered designations (by compelling manufacturers to disclose them), sort them into tiered review priorities, evaluate their scientific basis, and report findings publicly.
If the Board concludes a designation lacks evidence of safety, it must notify FDA and Congress; FDA may then revoke the designation after giving the manufacturer a statement of evidence, a 180‑day opportunity to submit rebuttal data, and a review. Noncompliant manufacturers can face civil penalties and FDA may treat substances as unapproved food additives.
The Board sunsets after 10 years and has specified reporting windows for tiered reviews.
At a Glance
What It Does
Creates a federal Board made up of FDA, USDA and other agency representatives to review manufacturer-made GRAS determinations made before 2000, categorize them into tiered priorities, and report outcomes publicly; the Board can recommend that FDA revoke a GRAS designation. The Secretary of HHS implements reviews, notifications, revocation procedures, and compliance timelines.
Who It Affects
Food manufacturers with GRAS determinations predating 2000 (including firms that never notified FDA), FDA and USDA program offices named to the Board, and downstream food processors/retailers that use affected substances. Public health advocates and consumers will be affected by any revocations and subsequent product changes or recalls.
Why It Matters
This bill would be the first statutory, interagency mechanism to systematically re-evaluate legacy GRAS decisions at scale, replacing ad hoc reviews with a structured, time‑bounded program that could alter market access for longstanding food ingredients.
More articles like this one.
A weekly email with all the latest developments on this topic.
What This Bill Actually Does
The bill builds a single-purpose review engine inside the federal system: the GRAS Review Board. It brings together voting representatives from HHS/FDA and USDA program and legal offices, plus a selected EPA toxicology division, and it allows the Secretary to add two non-voting appointees: an academic toxicologist and an industry representative.
Appointees serve five-year terms without pay; the Secretary chooses the chair from voting members. The Board’s statutory life is capped at ten years, after which the mechanism disappears.
To get a working list of candidate substances, the bill forces manufacturers to disclose any GRAS designation they hold that predates 2000 and was never petitioned or notified to FDA. That disclosure must occur within 90 days of enactment; the Secretary may use civil penalties (tied to existing FD&C Act penalty authority) or treat non-disclosed substances as unapproved food additives if manufacturers refuse to comply.
Once a substance is identified, the Board places it into tier 1, 2, or 3 to set review priority and must complete and publish reviews by statutory deadlines tied to those tiers (2, 4, and 10 years respectively).When the Board finds a designation unsupported by current safety evidence it must notify Congress and FDA within 90 days. FDA then has a defined revocation process: it must tell the manufacturer the evidence supporting revocation, provide 180 days for the manufacturer to submit contrary scientific data, re-evaluate using that material, and then notify the manufacturer of the final decision and the review rationale.
The statute also requires the Secretary to set compliance procedures and timelines for ceasing distribution and recalling products affected by a revocation.Transparency is built in: the Board must publish its reports and recommendations on FDA’s website. The statute also specifies practical enforcement levers — civil penalties drawn from section 307(a) of the FD&C Act and the option to treat a noncompliant substance as an unapproved food additive — giving FDA immediate administrative remedies while the evidentiary review runs.
Finally, the bill confines this program to legacy GRAS designations (pre-2000) and sunsets the Board and the Act after ten years, limiting the period for federal review and market impact.
The Five Things You Need to Know
Manufacturers must disclose all GRAS designations made before 2000 and never notified to FDA within 90 days of enactment or face penalties, including civil fines under FD&C Act §307(a) or having the substance treated as an unapproved food additive.
The statutorily created GRAS Review Board includes voting members from HHS/FDA, USDA program and legal offices, and the EPA’s Public Health and Integrated Toxicology Division, plus two non‑voting appointees (an academic food toxicologist and an industry representative).
The Board must categorize legacy GRAS items into tier 1, 2, or 3 and meet report deadlines of 2 years for tier 1, 4 years for tier 2, and 10 years for tier 3 after enactment.
If the Board recommends revocation, FDA must notify the manufacturer, provide 180 days for submission of scientific evidence to rebut the revocation, re‑review the evidence, and then issue a final decision and implementation plan (including recall/cessation timelines).
The Board and its authority expire 10 years after enactment; the statute is expressly time‑limited rather than creating a permanent program.
Section-by-Section Breakdown
Every bill we cover gets an analysis of its key sections.
Short title
Names the statute the 'GRAS Oversight and Transparency Act.' This is a standard enactment clause but signals Congress’s intent: oversight plus public reporting are central to the bill’s design.
Creates the GRAS Review Board
Directs the HHS Secretary, through the FDA Commissioner, to establish the Board to review 'covered GRAS designations.' Practically, this gives FDA an interagency forum with statutory authority to coordinate across USDA and EPA units that have technical or legal stake in food ingredient safety.
Board composition, appointment, and terms
Specifies voting membership (Secretaries of HHS and Agriculture, two Human Foods Program FDA reps, and single representatives from multiple USDA offices and EPA toxicology) and two non‑voting appointees. Members are appointed for five years and serve without pay; the Secretary selects the chair from voting members. For implementation this means multiple agencies will be formally tied into review deliberations and that internal agency rosters must identify delegates who can act with program and legal knowledge.
Review duties and stages
Requires the Board to define the scope of covered GRAS designations (via manufacturer disclosures), assign each to tier 1/2/3, perform scientific validity reviews, and publicly report results. The tiering establishes prioritization and directly maps to statutory reporting deadlines, forcing resource planning for which substances are reviewed first.
Manufacturer disclosure, enforcement, reporting timelines
Compels manufacturers to notify the Board within 90 days about covered GRAS designations and authorizes FDA to impose civil penalties per FD&C Act §307(a) or to treat non-disclosed substances as unapproved food additives. The Board must publish reports; tiered reviews are due at 2, 4, and 10 years. Operationally, firms will have a short window to inventory legacy GRAS positions and prepare to submit supporting dossiers.
Revocation procedures and manufacturer rebuttal
Gives FDA discretion to revoke a GRAS designation after the Board’s notification but sets process safeguards: FDA must notify the manufacturer of the evidence, allow 180 days to submit contrary science, re-evaluate, and then provide findings and rationale. The Secretary must also put in place compliance and recall timelines. These steps create an administrative record and an opportunity for scientific rebuttal before market-disruptive action.
Scope definitions and sunset
Defines 'covered GRAS designation' narrowly as manufacturer determinations made before 2000 that were never petitioned under section 409 or otherwise notified to FDA. The Board terminates and the Act ceases 10 years after enactment, making this a limited, legacy-focused program rather than an ongoing GRAS governance overhaul.
This bill is one of many.
Codify tracks hundreds of bills on Healthcare across all five countries.
Explore Healthcare in Codify Search →Who Benefits and Who Bears the Cost
Every bill creates winners and losers. Here's who stands to gain and who bears the cost.
Who Benefits
- Consumers and public-health advocates — will gain systematic, publicly available reviews of long-standing, previously opaque GRAS claims that could surface safety gaps and prompt product reformulation or clearer labeling.
- FDA and participating federal technical offices — receive a statutory, interagency process and explicit authority to evaluate legacy GRAS designations, creating a structured path for evidence-based enforcement and public reporting.
- Academic toxicologists and independent scientists — the review program creates opportunities to participate in or respond to reviews, and to shape the scientific record around legacy food substances.
Who Bears the Cost
- Food manufacturers with pre‑2000 GRAS determinations — must inventory and disclose legacy GRAS claims within 90 days, potentially assemble or defend scientific dossiers, face civil penalties for noncompliance, and may have products pulled or reformulated after revocation.
- Smaller firms and ingredient suppliers — may lack internal resources to compile historical safety data or defend designations within the 180‑day rebuttal window and could disproportionately bear costs of reformulation, relabeling, or recalls.
- FDA and partner agencies — must allocate staff time and scientific review capacity to meet tiered reporting schedules and to manage enforcement, disclosures, and potential recalls during the ten-year window.
Key Issues
The Core Tension
The bill pits two legitimate objectives: rapid, transparent reassessment of decades‑old, manufacturer‑determined safety claims to protect public health versus the legal, scientific, and commercial burden of re-proving safety for substances long in commerce — a trade-off between precautionary review and stability for businesses and supply chains.
The bill addresses a long-standing regulatory gap — legacy GRAS claims that were established by manufacturers without formal FDA review — but it raises implementation and legal questions. First, the statute blends advisory review (the Board’s findings) with potential enforcement (FDA revocation and use of food-additive status) while giving FDA discretion to revoke; that hybrid could generate litigation over standard of proof and whether the Board’s record alone suffices for revocation.
Second, the compressed timelines (90 days for manufacturer disclosure, 180 days to rebut revocation, and multi-year tier deadlines) create operational pressure. Manufacturers and agencies will need to sort decades-old, often proprietary safety data quickly; disputes over confidentiality and privileged information could slow reviews despite the statutory deadlines.
Third, the bill’s reliance on treating noncompliant substances as 'unapproved food additives' or on civil penalties provides FDA leverage, but both paths have different evidentiary and procedural requirements. Declaring a substance an unapproved additive invites challenges about past use, exposure assessment, and retroactive application of current safety expectations.
Finally, the ten-year sunset focuses the program on legacy issues but risks leaving unresolved substances at the program’s end or creating a staggered, piecemeal market disruption as revocations and compliance activities play out over a decade.
Try it yourself.
Ask a question in plain English, or pick a topic below. Results in seconds.